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SUMMARY
The activation of the JAK1/JAK2 pathway plays a crucial role in the pathogenesis of 
myelofibrosis. Treatment with the JAK2 inhibitor ruxolitinib demonstrated to reduce sple-
nomegaly and symptoms in patients affected by myelofibrosis, leading to a significant 
improvement of overall survival in comparison with the supportive therapies. Taking 
in account this recent therapeutic progress, it is necessary to redefine the role of the 
allogeneic hematopoietic stem cell transplantation, which has been considered the 
only curative option for fit myelofibrosis patients up to now. In the era of JAK2 inhibi-
tors, allogeneic transplant is still indicated in patients with intermediate-2 and high-risk 
myelofibrosis or red blood cell transfusion dependent patients or patients with unfavour-
able karyotype. There is no direct evidence to recommend which conditioning regimen 
should be preferentially adopted. Graft failure, relapse and transplant related mortality 
are still current issues of the allogeneic stem cell transplantation, particularly from un-
related donors. Ruxolitinib can be efficaciously included in the platform of allogeneic 
transplant. In fact, ruxolitinib treatment for 3-4 months before transplant has demon-
strated to reduce spleen and improve performance status in about 30-50% of patients, 
without impairing the outcome of the subsequent transplant. Ruxolitinib has to stopped 
the day before conditioning to avoid rebound phenomenon. There are no sufficient 
data to recommend ruxolitinib administration after transplant with the aim of eradicat-
ing minimal residual disease and preventing relapse. 
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REVIEW
◗◗◗ INTRODUCTION
Myelofibrosis (MF) is one of the classical 
BCR-ABL negative chronic myeloprolif-
erative neoplasms (MPN), a group also 
including essential thrombocythemia 
(ET), and polycythemia vera (PV). The 
term MF is comprehensive of idiopath-
ic or primary myelofibrosis, the most fre-
quent form, PV-related MF and ET-re-
lated MF, with a similar presentation 
and clinical course (1,2). The disease is 
characterized by a clonal proliferation 
of a pluripotent stem cell associated 
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with an abnormal release of several cy-
tokines and growth factors which lead 
to fibrosis, osteosclerosis, angiogene-
sis and extramedullary hematopoiesis 
associated with hepatosplenomegaly 
(3). The JAK2V617F mutation is found in 
97% of patients affected by PV and in 
60% of those affected by ET and MF. 
The JAK2 protein has a tyrosine kinase 
activity and the gain of function V617F 
mutation determines constitutional 
activation of the JAK/STAT pathway. 
The mutation in the thrombopoietin re-
ceptor gene (MPL) is reported in 8% of 
patients with MF. To underline the im-
portance of the genetic component, 
in 2008 the World Health Organization 
(WHO) released the new diagnostic 
criteria for MF including the presence 
of these mutations in the major ones 
(4). Another crucial discovery was 
made in the 2013, when the somatic 
mutation of CALR, the gene encoding 
for calreticulin, was found in 20 to 25% 
of patients with ET or MF. Subsequently, 
several gene mutations including CBL, 
LNK, TET2, ASXL1, IDH1, IDH2 and IKZF 
have been reported in MPNs (2).
◗◗◗ CLINICAL FEATURES
The disease affects mainly elderly 
people with a median age at diag-
nosis of 65 years, men and women in 
equal percentage, but young people 
are not necessarily spared (1). Clinical 
manifestations are heterogeneous: at 
diagnosis nearly 30% of patients can 
be asymptomatic. The most common 
symptoms include severe anemia, 
constitutional symptoms (e.g. fatigue, 
night sweat and fever), bone pain, 
aquagenic pruritus and marked sple-
nomegaly causing abdominal pain 
and early satiety. Portal and pulmo-
nary hypertension can be observed 
(3, 4). The median overall survival (OS) 
of MF is nowadays ranges from 2 to 15 
years (1). The main causes of death are 
infections, hemorrhage complications 
due to bone marrow (BM) failure, the 
evolution of the MF into acute leuke-
mia, which can be observed in the 20% 
of the patients, and other complica-
tions linked to portal hypertension (5).
◗◗◗ PROGNOSTIC SCORES
Since 2009 the International Prognostic 
Scoring System (IPSS) has been adopt-
ed: it is applicable at the presentation 
of the disease and identifies for risk cat-
egories: low, intermediate-1, interme-
diate-2 and high, based on five clini-
cal features which are: age >65 years, 
hemoglobin <10g/dL, leukocyte count 
>25x109 /L, circulating blasts >1% and 
constitutional symptoms, assigning 
them one point each. The correspond-
ing median OS per each category is 
11.3, 7.9, 4 and 2.3 years. 
The International Working Group for 
Myelofibrosis Research and Treatment 
(IWGMR) subsequently developed a 
dynamic prognostic model named 
DIPSS, that uses the same predictors, 
but it can be applied at any time 
during the disease course, and assigns 
two, instead of one adverse point, to 
the lower level of hemoglobin. Later, 
three other independent factors were 
added to the DIPPS: the presence of 
unfavorable karyotype (e.g.+8, −7/7q-
, i(17q), −5/5q-, 12p-, inv(3) or 11q23 
rearrangement ), the need of red cell 
transfusion and the platelets count 
<100x109/L, leading to the DIPSS-PLUS 
(Table 1) (6-8).
The gene mutations are not included in 
the prognostic scores, but several stud-
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ies have been underlined their prog-
nostic impact. The triple negative asso-
ciation (JAK2, MPL and CALR) predicts 
poor diagnosis, while isolated CALR 
mutation in combination with favor-
able clinical variables (higher platelets 
count, lower circulating leukocytes, 
higher hemoglobin level) seems to be 
linked with better prognosis (9, 10). 
◗◗◗ TREATMENT 
Conventional treatment
Therapy for MF is conventionally based 
on the patient risk category, age and 
presenting disease manifestations. Be-
fore the introduction of JAK2 inhibitors, 
MF treatment was mainly palliative 
and was focused to improve clinical 
symptoms, for example hydrossiurea or 
busulfan for leukocytosis and danazol 
or thalidomide for anemia.
Ruxolitinib, an oral potent and selec-
tive JAK1/JAK2 tyrosine kinase inhibitor, 
was approved by FDA in 2011 and by 
EMA in 2012 the treatment of interme-
diate and high risk MF. It prevents ac-
tivation of JAK-STAT signaling pathway 
and acts by reducing proliferation of 
MNP clone and by releasing inflamma-
tory molecules (2).
Two randomized studies comparing 
ruxolitinib with placebo or best avail-
able therapy (BAT) have been pub-
lished. In the COMFORT-I, a random-
ized, double blind phase 3 study, rux-
olitinib was compared with placebo. 
The spleen volume reduction of 35% 
or more after 24 weeks was gained 
by 41.9% of patients in the ruxolitinib 
group and 0.7% in the placebo group. 
About 46% of patients who received 
ruxolitinib experienced an improve-
ment of symptoms. The most common 
adverse events in the ruxolitinib arm 
were anemia (31%) and thrombocyto-
penia (34.2%).
In the COMFORT-II, a randomized 
phase 3 trial, ruxolitinib was compared 
with BAT and it displays similar findings 
of marked durable reduction in spleen 
volume and in performance status (11). 
A recent study update demonstrated 
that 53.4% of patients in the ruxolitinib 
arm achieved a spleen reduction last-
ing for 3.2 years and 48% of patients 
TABLE 1 • Prognostic score systems.
IPSS(6) DIPSS(7) DIPSS-PLUS(8)
Variables • Age>65y
• Hb <10 gr/dL
• Leukocyte count 
>25x109/L
• Blasts>1%
• Constitutional 
symptoms
• Age >65y
• Hb <10 gr/dL
• Leukocyte count 
>25x109/L
• Blasts >1%
• Constitutional 
symptoms
• Age >65y
• Hb <10 gr/dL
• Leukocyte count >25x109/L
• Blasts >1%
• Constitutional symptoms
• Platelets count <100x109/L
• RBC transfusion need
• Unfavorable karyotype*
Score 1 point each 1 point each
Hb: 2 points
1 point each
Risk Low 0
Intermediate-1 1
Intermediate-2 2
High 3
Low 0
Intermediate-1 1-2
Intermediate-2 3-4
High 5-6
Low 0
Intermediate-1 1
Intermediate-2 2-3
High 4-6
*unfavorable karyotype (e.g.+8, −7/7q-, i(17q), −5/5q-, 12p-, inv(3) or 11q23 rearrangement.
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improved or stabilized bone marrow 
fibrosis. Although the longer exposure, 
there was no increase of the side ef-
fects in comparison with previous stud-
ies. The risk of death was reduced by 
33% in the ruxolitinib arm (12-14).
Allogeneic stem cell transplant 
Allogeneic stem cell transplantation 
(allo-SCT) is the only potentially cura-
tive option for MF patients and is typ-
ically reserved for fit patients, whose 
life expectancy is shorter than 3 years, 
including DIPPS intermediate-2 and 
high-risk individuals and patients with 
unfavorable cytogenetic abnormali-
ties. 
Since the initial report of successful al-
lo-SCT in MF (15), several publications 
have confirmed the curative poten-
tial of transplantation, and the adop-
tion of reduced intensity conditioning 
(RIC) regimens has made allo-SCT 
applicable to a larger proportion of 
patients (16). However, there are no 
randomized controlled trials compar-
ing allo-SCT with any drug therapy or 
supportive care; nor are there any 
randomized controlled trials compar-
ing myeloablative conditioning (MAC) 
with RIC allo-SCT. 
In the choice of allo-SCT for MF, we 
should take into account either the 
prognosis of disease or the incidence 
of morbidity and mortality related to 
the transplant procedure.
Allogeneic transplant: patient selection
The choice of allo-SCT can be based 
on the prognostic score of the pa-
tients which predicts the outcome 
of the disease at diagnosis and at 
any time of MF evolution. Population 
based non controlled studies had 
demonstrated that median OS after 
allo-SCT was superior to that after non 
transplant management in patients 
with DIPPS intermediate-2 and high-
risk score (17-21). 
Taking into account either prognostic 
scoring systems and the more recent 
molecular risk classification, the follow-
ing categories should be considered 
potential candidates for allo-SCT:
1. All patients with intermediate-2 or 
high-risk disease according to IPSS, 
DIPPS or DIPSS Plus, and age <70 
years; 
2. All patients with intermediate-1 risk 
disease, age <65 years with either 
refractory, transfusion-dependent 
anemia or a percentage of blasts in 
peripheral blood major than 2%, or 
adverse cytogenetics.
Patients with low–risk disease should 
not undergo allo-SCT: they should be 
monitored and evaluated for trans-
plantation if disease progression oc-
curs. Patients with blastic transforma-
tion should receive debulking therapy 
and be reconsidered for transplant 
after achieving at least a partial remis-
sion. Although molecular risk classifica-
tion for the identification of candidates 
for allo-SCT among intermediate-1 risk 
patients deserves further clinical val-
idation, patients in this risk catego-
ry who are JAKV617F, CALR and MLP 
negative or ASXL1 positive, or both, 
should be considered for transplant.
Allogeneic transplant: choice of 
conditioning regimen
Clinical results of standard MAC trans-
plants were reported since 1999 and 
resulted in non relapse mortality (NRM) 
rates ranging from 27 to 48% with more 
favorable results in fit young patients 
with less advanced disease and better 
HLA-matching (Table 2) (1, 22-28).
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In the CIMTR retrospective analysis (10) 
ideal candidates for MAC were pa-
tients younger than 40 years, with no 
comorbidities and an HLA-identical 
sibling.
In the last decade, several retrospec-
tive and prospective studies have 
demonstrated feasibility of RIC regi-
mens with NRM rates ranging from 9 to 
54% and OS ranging from 34 to 78% (Ta-
ble 3) (6, 21, 29-36). A spectrum of RIC 
regimens and protocols has shown ac-
ceptable NRM and OS. Two prospec-
tive studies have been published: Kro-
eger et al. (29) reported in 104 patients 
treated with a fludarabine-busulfan 
conditioning an encouraging 5-year 
OS of 67%, with 2 year-NRM of 16%. A 
subsequent study reported by Rondelli 
et al. (21) with a fludarabin-melphalan 
preparative regimen observed a sig-
nificantly poorer outcome after unre-
lated donor transplants in comparison 
with HLA-identical sibling transplants, 
due to toxicity and graft failure. Now 
days, there is no direct evidence to 
TABLE 2 • Myeloablative allogeneic stem cell transplant for Myelofibrosis.
N. 
patients
Median 
age Conditioning
Graft 
failure NRM*
Relapse 
rate OS**
Guardiola  
et al. (22)
55 42 (4-53) MAC 9% 27% 23% 47%
Daly A. et al. (23) 25 48 (46-50) MAC 9% 48% / 41%
Ditschkowski M.  
et al. (24)
20 45 (22-57) MAC n.v. 40% 15% 38%
Kerbauy  
et al. (25)
104 49 (18-70) 91% MAC 10% 34% 10% 51%
Patriarca F.  
et al. (1)
100 49 (21-68) 49% MAC 10% 43% 41% 42%
Stewart W.A.  
et al. (26)
51 49 (19-64) 52% MAC 0 41% 15% 44%
Balle K.K.  
et al. (27)
289 47 (18-73) 86% MAC 18% 36% 32% 36%
*NMR = non relapse mortality; **OS = overall survival.
TABLE 3 • Reduced Intensity stem cell transplant for Myelofibrosis.
N. patients Median age NRM* Relapse rate OS**
Rondelli D. et al. (32) 21 54 (27-68) 9% 9% 78%
Merup M. et al. (33) 10 40 (5-63) 29% NE 70%
Bacigalupo A. et al. (35) 46 55 (32-68) 24% 19% 45%
Nagi W. et al. (36) 11 51(46-62) 54% 0 46%
Samuelson S. et al. (37) 30 65 (60-78) 30% 30% 45%
Gupta V. et al. (6) 233 55(19-79) 24% 48% 56%
Kroger N. et al. (29) 104 55(32-68) 16% - 67%
Rondelli D. et al. (21) 66 54.5 40.5% - 53.5%
*NMR = non relapse mortality; **OS = overall survival.
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recommend which conditioning regi-
men should be preferentially adopted, 
due to the lack of comparative studies. 
A phase II randomized study compar-
ing 2 fludarabin-based RIC regimens 
associated with a different alkylating 
agent (busulfan versus thiotepa) has 
been conducted by the Gruppo Italia-
no Trapianto di Midollo Osseo (GITMO) 
and the clinical results of this trial will 
clarify this issue. Moreover, the optimal 
intensity of the conditioning regimen 
still needs to be defined: for patients 
with older age or with comorbidities, or 
both, a lower intensity regimen is more 
appropriate, while for patients with 
advanced disease and good perfor-
mance status a more intensive regi-
men should be selected.
Allogeneic transplant: management 
and prevention of relapse
About 10-18% of MF patients trans-
planted with MAC regimens expe-
rienced relapse within 3 years post 
transplant (23,25,27,28). Relapse rates 
after RIC ranged from 29 to 43% (20, 
21). Disease-specific markers such as 
karyotypic abnormality, JAK2V617F, 
CALR and MPL mutations should be 
monitored to detect minimal residual 
disease after allo-SCT. Timing of anal-
ysis should be paired with chimerism 
evaluation.
Alchalby et al. (37) evaluated the im-
pact of JAK2 genotype, JAK2V617F 
allele burden and clearance of muta-
tion after allo-SCT in 139 MF patients. 
OS was significantly reduced in multi-
variate analysis in patients harboring 
JAK2 wild-type compared with JAK2 
mutated patients. No significantly influ-
ence on outcome was noted for the 
mutated allele burden. Achievement 
of JAK2V617F negativity after allo-SCT 
was significantly associated with a de-
creased incidence of relapse.
In patients with evidence of minimal 
residual disease or with decreasing 
donor cell chimerism, discontinuation 
of immune-suppressive drugs and/or 
escalated donor lymphocyte infusions 
(DLI) should be considered to avoid 
clinical relapse.
In patients who relapse after allo-SCT 
and do not have severe GvHD, reduc-
tion of immunosuppressive drugs or DLI 
are the treatment strategies of choice: 
JAK inhibitor treatment is recommend-
ed, but remains experimental.
Allogeneic transplant: how to include 
JAK2 inhibitors in the platform of 
allogeneic transplant  
Taking in account their mechanism of 
action and biological effects, the JAK2 
inhibitors have a potential impact on 
several steps of the MF treatment path-
way. This influence could theoretically 
be favourable or negative. First, if they 
are administered in the pre-transplant 
period, they can enhance feasibility 
of the procedure, improving perfor-
mance status and reducing spleno-
megaly. However, patients respon-
sive to JAK2 inhibitors would be more 
likely to defer or avoid transplant, at 
least temporarily, and they could be 
candidate for it after having lost the 
response and in presence of more ad-
vanced disease.   
Second, the inclusion of the JAK2 in-
hibitors into the conditioning regimen 
could lower the inflammatory cyto-
kines and reduce GvHD risk, but at the 
same time, could alter the engraft-
ment dynamic. Third, consolidation or 
maintenance with JAK2 inhibitors af-
ter allo-SCT could eradicate minimal 
residual disease; however, an impact 
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on lymphoid reconstitution can be hy-
pothesized.  
Since 2010, a few prospective trials 
incorporating JAK-2 inhibitors in the 
platform of allogeneic transplant 
have been initiate (Clinical Trials. 
Gov NCT01790295; Clinical Trial. gov: 
NCT01795677), but conclusive results 
have not been reported yet; more-
over, some retrospective studies were 
already published (38-40). 
All these data concern exclusively rux-
olitinib administered in the pre-trans-
plant period. 
The first information came from the ab-
stract presented at the American Soci-
ety Haematology Meeting in Decem-
ber 2013 by the French group, which 
reported 10 severe adverse events oc-
curring within 21 days after ruxolitinib 
discontinuation (39). 
These events, including tumour lysis syn-
dromes or cardiogenic shocks, which 
occurred during conditioning regimen 
or in the early period after stem cell 
reinfusion, had some clinical features 
in common with the withdrawal syn-
drome already reported after abrupt 
suspension of ruxolitinib outside the 
transplant setting (41) and attributed 
to a rapid rebound of inflammatory 
cytokines. 
These adverse effects can be pre-
vented by slowly tapering rather than 
abruptly discontinuing ruxolitinib. In 
fact, a few retrospective studies (39, 
40, 42) in which ruxolitinib was tapered 
and suspended the day(s) before con-
ditioning did not reported any severe 
toxicity. Moreover, these trials reported 
that ruxolitinib reduced splenomegaly 
or control symptoms in the majority of 
the patients treated before transplant, 
with occasional severe haematolog-
ical adverse effects. All patients en-
grafted after transplant and incidence 
of acute GvHD and NRM were in the 
ranges expected after allo-SCT for MF 
patients. 
The largest retrospective study (43) in-
cluded 100 pts treated with ruxolitinib 
before allo-SCT among different Ca-
nadian and American Centers. Out-
come of ruxolitinib treatment before 
allo-SCT could be differentiated in 5 
conditions: clinical improvement (23 
patients), stable disease (31 pts), cy-
topenia or intolerance (18 pts), pro-
gressive splenomegaly (18 pts), leuke-
mic transformation: (13 pts). Patients 
who obtained clinical improvement 
with ruxolitinib before transplant had 
a significative reduction of NRM and 
relapse incidence and a significative 
prolongation of OS after transplant. 
Moreover, response to JAK2 inhibitors, 
DIPSS and donor type emerged as in-
dependent predictors for OS. 
Adverse events related to withdraw-
al syndrome were significantly more 
common in patients who started ta-
pering or stopped more that 6 days 
before conditioning. The consensus 
of European Bone Marrow Transplan-
tation (EBMT)/European Network Leu-
kaemia (ENL) (44) has proposed some 
guidelines regarding inclusion of ruxoli-
tinib in transplant platform. The experts 
stated that pre-transplant JAK inhibitor 
therapy is indicated in patients with 
symptomatic spleen and/or constitu-
tional symptoms. 
The drug should be initiated at least 2 
months before transplant and should 
be titrated to the maximum tolerat-
ed dose. Weaning starting to 5-7 days 
prior to conditioning should be imple-
mented in the attempt to avoid a re-
bound phenomenon, with the drug 
stopping the day before conditioning. 
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JAK2 inhibitors alone may reduce the 
spleen size and persistent constitution-
al symptoms, but there is no evidence 
that suggests modulation of donor cell 
chimerism or clearance of minimal re-
sidual disease: therefore no guideline 
regarding ruxolitinib administration af-
ter transplant can be proposed.  
◗◗◗ CONCLUSIVE CONSIDERATIONS
In conclusion, the indications of the 
EBMT/ENL consensus (44) are the fol-
lowing: 
• All patients with intermediate-2 or 
high-risk MF and age <70 years, 
should be considered candidates 
for allo-SCT;
• Patients with intermediate-1 disease 
and age <65 years should be con-
sidered for allo-SCT if transfusion 
dependent anemia, or blasts in pe-
ripheral blood >2% or adverse cyto-
genetics are present;
• Patients with low-risk disease should 
not be considered for transplant;
• Patients can receive ruxolitinib be-
fore transplant to reduce spleno-
megaly and symptoms and have to 
stop it the day before conditioning; 
• The optimal intensity of the condi-
tioning regimen still needs to be de-
fined;
• A spectrum of reduced intensi-
ty conditioning and protocols has 
shown acceptable NRM and OS;
• Disease–specific markers (in partic-
ular JAK2V67F) should be monitored 
to detect minimal residuals disease 
after allo-SCT.
• Ruxolitinib administration after trans-
plant with the aim of modulating 
donor cell chimerism or eradicating 
minimal residual disease warrants 
further exploration.   
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